Meeting
2022 ASCO Annual Meeting
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.
Authors
Niels W.C.J. van de Donk
Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Niels W.C.J. van de Donk , Mounzer E. Agha , Adam D. Cohen , Yael C. Cohen , Sébastien Anguille , Tessa Kerre , Wilfried Roeloffzen , Jordan Mark Schecter , Kevin C. De Braganca , Helen Varsos , Pankaj Mistry , Tito Roccia , Enrique Zudaire , Christina Corsale , Muhammad Akram , Dong Geng , Tonia Nesheiwat , Lida Bubuteishvili-Pacaud , Pieter Sonneveld , Sonja Zweegman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT04133636
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8029)
DOI
10.1200/JCO.2022.40.16_suppl.8029
Abstract #
8029
Poster Bd #
453
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.
First Author: Hermann Einsele
Poster
2024 ASCO Annual Meeting
Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.
First Author: Radhika Bansal
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang